3199-71-1

Usage

Uses

Used in Pharmaceutical Industry:
4-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL is used as a key intermediate in the synthesis of various pharmaceuticals due to its unique structural features and reactivity. It contributes to the development of new drugs by facilitating the creation of diverse chemical entities with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, 4-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL serves as an essential building block for the production of agrochemicals. Its incorporation into these compounds aids in the development of effective pesticides, herbicides, and other agricultural products that enhance crop protection and yield.
Used in Organic Synthesis:
4-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL is utilized as a versatile reactant in organic synthesis. Its functional groups and reactivity enable the formation of a wide range of organic compounds, which can be further used in various applications, including the production of specialty chemicals and materials.
Used in Medicinal Chemistry:
4-CHLORO-2,3-DIHYDRO-1H-INDEN-1-OL plays a significant role in medicinal chemistry, where it is employed for the design and synthesis of novel bioactive molecules. Its structural features and reactivity allow for the exploration of new chemical space, potentially leading to the discovery of innovative therapeutic agents.

InChI:InChI=1/C9H9ClO/c10-8-3-1-2-7-6(8)4-5-9(7)11/h1-3,9,11H,4-5H2

Upstream product

• 15115-59-0 4-chloro-2,3-dihydro-1H-inden-1-one 
• 30573-88-7 ethyl 3-(2-chlorophenyl)propanoate 
• 83-33-0 inden-1-one 
• 89-98-5 2-chloro-benzaldehyde 
• 24393-51-9 (E)-ethyl 2-chlorocinnamate 
• 1643-28-3 3-(2-chlorophenyl)propanoic acid 

Downstream Products

• 52085-99-1 7-chloro-1H-indene 

Relevant academic research and scientific papers

Tetrahydrofuran-Based Transient Receptor Potential Ankyrin 1 (TRPA1) Antagonists: Ligand-Based Discovery, Activity in a Rodent Asthma Model, and Mechanism-of-Action via Cryogenic Electron Microscopy

Transient receptor potential ankyrin 1 (TRPA1) is a nonselective calcium-permeable ion channel highly expressed in the primary sensory neurons functioning as a polymodal sensor for exogenous and endogenous stimuli and has generated widespread interest as a target for inhibition due to its implication in neuropathic pain and respiratory disease. Herein, we describe the optimization of a series of potent, selective, and orally bioavailable TRPA1 small molecule antagonists, leading to the discovery of a novel tetrahydrofuran-based linker. Given the balance of physicochemical properties and strong in vivo target engagement in a rat AITC-induced pain assay, compound 20 was progressed into a guinea pig ovalbumin asthma model where it exhibited significant dose-dependent reduction of inflammatory response. Furthermore, the structure of the TRPA1 channel bound to compound 21 was determined via cryogenic electron microscopy to a resolution of 3 ?, revealing the binding site and mechanism of action for this class of antagonists.

CYCLIC COMPOUNDS

The present invention provides compounds having a Toll-like receptor 4 (TLR4) signaling inhibitory action useful as preventive and therapeutic drugs of inflammatory disease and/or central nervous system disease or diseases such as chemotherapy-induced peripheral neuropathy (CIPN), chemotherapy-induced neuropathic pain (CINP), liver injury, ischemia-reperfusion injury (IRI) and the like. The present invention relates to a compound represented by formula (I) and a salt thereof: (wherein, each symbol is explained in greater detail in the specification).

SUBSTITUTED HETEROCYCLIC DERIVATIVES AS GPR AGONISTS AND USES THEREOF

The present invention generally relates to substituted heterocyclic derivatives (the compounds of Formula (I)), processes for their preparation, pharmaceutical compositions containing said compounds, their use as G-protein coupled receptor (GPR) agonists, particularly as GPR40 agonists and methods of using these compounds in the treatment of GPR40 mediated diseases or conditions such as Type 2 diabetes, obesity, dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.

NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE

[Problem] To provide a GPR40 activating agent having, as an active ingredient, a novel compound having a GPR40 agonist action, a salt of the compound, a solvate of the salt or the compound, or the like, particularly, an insulin secretagogue and a prophylactic and/or therapeutic agent against diabetes, obesity, or other diseases. [Means of solving the problem] A compound of Formula (I): (where p is 0 to 4; j is 0 to 3; k is 0 to 2; a ring A is a specific cyclic group; a ring B is a benzene ring, a pyridine ring, or a pyrimidine ring; X is —CH2—, O, —S(O)i— (i is 0 to 2), or —NR7—; R1 to R6 are specific groups), a salt of the compound, or a solvate of the salt or the compound.

Synthesis and biological evaluation of novel 2,4-diaminoquinazoline derivatives as SMN2 promoter activators for the potential treatment of spinal muscular atrophy

Proximal spinal muscular atrophy (SMA) is an autosomal recessive disorder characterized by death of motor neurons in the spinal cord that is caused by deletion and/or mutation of the survival motor neuron gene (SMN1). Adjacent to SMN1 are a variable number of copies of the SMN2 gene. The two genes essentially differ by a single nucleotide, which causes the majority of the RNA transcripts from SMN2 to lack exon 7. Although both SMN1 and SMN2 encode the same Smn protein amino acid sequence, the loss of SMN1 and incorrect splicing of SMN2 have the consequence that Smn protein levels are insufficient for the survival of motor neurons. The therapeutic goal of our medicinal chemistry effort was to identify small-molecule activators of the SMN2 promoter that, by up-regulating gene transcription, would produce greater quantities of full-length Smn protein. Our initial medicinal chemistry effort explored a series of C5 substituted benzyl ether based 2,4-diaminoquinazoline derivatives that were found to be potent activators of the SMN2 promoter; however, inhibition of DHFR was shown to be an off-target activity that was linked to ATP depletion. We used a structure-guided approach to overcome DHFR inhibition while retaining SMN2 promoter activation. A lead compound 11a was identified as having high potency (EC50 = 4 nM) and 2.3-fold induction of the SMN2 promoter. Compound 11a possessed desirable pharmaceutical properties, including excellent brain exposure and long brain half-life following oral dosing to mice. The piperidine compound 11a up-regulated expression of the mouse SMN gene in NSC-34 cells, a mouse motor neuron hybrid cell line. In type 1 SMA patient fibroblasts, compound 11a induced Smn in a dose-dependent manner when analyzed by immunoblotting and increased the number of intranuclear particles called gems. The compound restored gems numbers in type I SMA patient fibroblasts to levels near unaffected genetic carriers of SMA.

Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/- indanes and structurally modified derivatives: Potent and selective inhibitors of aldosterone synthase

Elevated aldosterone levels are key effectors for the development and progression of congestive heart failure and myocardial fibrosis. Recently, we proposed inhibition of aldosterone synthase (CYP11B2) as an innovative strategy for the treatment of these

SYNTHESE TOTALE DE STEROIDES A CYCLE C AROMATIQUE

The ring-C aromatic analogue 4 of 4-androstene 3,17-dione and its 11 hydroxylated(methoxylated) derivatives 20a(b) were prepared by a practical synthetic route.The key steps of the sequence are achieved in superacid: the cyclisation of diarylethane 5a to phenanthrenone 17, and the hydroxylation by hydrogenperoxide of ketone 4 to phenol 20a.

Pharmaceutical compositions and method of inhibiting phenylethanolamine N-methyltransferase

Pharmaceutical compositions and methods of inhibiting phenylethanolamine N-methyltransferase using 2-indanamine compounds having 4 and/or 5 substituents.